Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2024 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司同类业务连续接洽的规模在逐步扩大。需要寻找管理层关于订单、合同、项目、客户、站点或项目规模增大的表述,并与公司自身过去进行比较,且这种增大是已实现、正在发生的,并且是早期的。 在记录中,管理层提到了多个业务领域,如NanoKnife、Auryon、机械血栓切除等。但我们需要寻找关于“单位规模”增大的明确表述。例如,是否提到新客户一开始就达到旧客户多年后的水平,或者从单件销售变为批量销售,或者合同规模变大等。 检查记录内容: - 关于NanoKnife,提到增长36%,但主要是销售增长,未提及单个订单或客户规模增大。 - 关于Auryon,提到增长26%,但未提及单个设备或合同规模变化。 - 关于机械血栓切除,提到AngioVac稳定,AlphaVac增长,但未提及规模增大。 - 关于国际业务,提到增长26%,但未提及单个合同规模。 - 关于Med Device,提到端口增长22%,但未提及规模。 管理层没有明确说“新订单的平均规模比过去大”或“客户现在一开始就购买更多”等。他们主要谈论的是收入增长、市场份额、产品采用等,但未涉及单位规模升级。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.